CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2026)
CRISPR Therapeutics AG's (CRSP) quarterly Operating Margin came in at 1151.84% in Q2 2026, up 2455713.0% year-over-year from N/an in Q2 2025, and up 87.11% quarter-over-quarter from 8933.33% in Q1 2026.
Powered by 
Analysis
CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has disclosed Operating Margin across 11 years of filings, most recently posting 1151.84% for Q2 2026.
- In Q2 2026, Operating Margin rose 2455713.0% year-over-year to 1151.84%; the TTM figure through Jun 2026 stood at 3989.99% (down 253805.0% YoY), while the FY2025 annual figure was 18933.65%, down 1768327.0% from the prior year.
- Operating Margin came in at 1151.84% for Q2 2026 at CRISPR Therapeutics AG, up from 8933.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 34.58% in Q4 2023 to a low of 2192350.0% in Q4 2022.
- Average Operating Margin over 5 years is 157800.01%, with a median of 17912.5% recorded in 2025.
- Year-over-year, Operating Margin sank 219122047 bps in 2022 and surged 219238458 bps in 2023.
- Over 5 years, Operating Margin stood at 2192350.0% in 2022, then surged by 100 bps to 34.58% in 2023, then plunged by 623 bps to 180.96% in 2024, then sank by 9798 bps to 17912.5% in 2025, then surged by 94 bps to 1151.84% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 1151.84% in Q2 2026, 8933.33% in Q1 2026, and 17912.5% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 0.56% |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,151.84% |
| Mar 31, 2026 | -8,933.33% |
| Dec 31, 2025 | -17,912.50% |
| Sep 30, 2025 | -14,854.78% |
| Jun 30, 2025 | -25,708.97% |
| Mar 31, 2025 | -17,158.84% |
| Dec 31, 2024 | -180.96% |
| Sep 30, 2024 | -18,294.02% |
| Jun 30, 2024 | -29,257.25% |
| Mar 31, 2024 | -27,894.25% |
| Dec 31, 2023 | 34.58% |
| Jun 30, 2023 | -136.03% |
| Mar 31, 2023 | -64.49% |
| Dec 31, 2022 | -2,192,350.00% |
| Sep 30, 2022 | -194,029.79% |
| Jun 30, 2022 | -115,987.34% |
| Mar 31, 2022 | -18,720.43% |
| Dec 31, 2021 | -1,129.53% |
| Sep 30, 2021 | -15,637.01% |
| Jun 30, 2021 | 84.67% |